PRINCETON, N.J., April 30, 2026 /PRNewswire/ -- Made Scientific, a U.S.-based contract development and manufacturing organization (CDMO) specializing in cell therapies, today announced the continued build-out of its

<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">PRINCETON, N.J.</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">April 30, 2026</span> /PRNewswire/ -- Made Scientific, a U.S.-based contract development and manufacturing organization (CDMO) specializing in cell therapies, today announced the continued build-out of its Board of Directors, including the appointment of Ted Dolan and Soyoung Park. They join Jin Pyun, Harry S. Rathore, Ph.D., and Yonghoon Kim, alongside Chairman and CEO Syed T. Husain, as part of a deliberate effort to align the company&#39;s governance with its next phase of growth.</p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                        <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/2642492/Made_Scientific_Logo.html" target="_blank" rel="nofollow">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/2642492/Made_Scientific_Logo.jpg" title="Made Scientific, Inc. (PRNewsfoto/Made Scientific, Inc)" alt="Made Scientific, Inc. (PRNewsfoto/Made Scientific, Inc)"></img>
                        </a>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">Over the past year, Made Scientific has assembled a Board with deep experience spanning CDMO operations, global commercialization, the broader healthcare ecosystem, strategic planning, and financial stewardship. With these additions, the Board further strengthens its ability to support the company&#39;s transition toward late-phase and commercial cell therapy manufacturing.</p><p xmlns="http://www.w3.org/1999/xhtml">This evolution comes as Made Scientific expands its GMP manufacturing capacity at its Princeton, NJ campus to meet increasing demand from advanced therapy developers. As programs move closer to commercialization, the ability to scale operations, ensure operational discipline, and execute reliably becomes critical — areas where the Board brings direct, relevant experience.</p><p xmlns="http://www.w3.org/1999/xhtml">Made Scientific is supported by GC Corporation, a long-term strategic shareholder providing stability, global perspective, and sustained investment in the business. This partnership reflects a shared commitment to building deliberately — prioritizing scale and quality over short-term outcomes — and positions Made Scientific to advance cell therapy manufacturing with a long-term vision.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;As both Chairman and CEO, I&#39;ve been very intentional about how we&#39;ve built this Board over time,&#34; said Syed T. Husain. &#34;These are leaders who understand how to scale in complex environments and how therapies move through the broader healthcare ecosystem. With the addition of Ted and Soyoung, we are even better positioned to execute as we expand capacity, support increasingly complex and late-stage programs, and continue progressing toward becoming a leading cell therapy CDMO partner.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">Board of Directors</p><p xmlns="http://www.w3.org/1999/xhtml">SYED T. HUSAIN</p><p xmlns="http://www.w3.org/1999/xhtml">Syed T. Husain serves as Chairman and Chief Executive Officer of Made Scientific, bringing deep experience across the CDMO spectrum from development through commercialization of established and emerging therapeutic modalities, and leading the company&#39;s evolution toward late-phase and commercial cell therapy manufacturing. He previously served as Chief Commercial Officer at Resilience, where he drove commercial growth and established strategic partnerships. Earlier in his career, he held senior leadership roles at Emergent BioSolutions, Alcami Corporation, and Lonza.</p><p xmlns="http://www.w3.org/1999/xhtml">TED DOLAN</p><p xmlns="http://www.w3.org/1999/xhtml">Ted Dolan brings more than 40 years of CDMO and pharmaceutical manufacturing leadership across drug substance, drug product, and analytical services. He most recently served as COO of BioVectra and has held senior leadership roles at Alcami, Lonza, and Johnson Matthey. He adds deep operational expertise in scaling manufacturing organizations and driving execution across complex programs.</p><p xmlns="http://www.w3.org/1999/xhtml">YONGHOON KIM</p><p xmlns="http://www.w3.org/1999/xhtml">Yonghoon Kim brings extensive experience in global investment and financial management. He currently serves as CFO of MOHABI Investment USA, Inc., with prior experience at international investment and accounting firms including PwC Korea and NH Investment &amp; Securities (formerly Woori Investment &amp; Securities).</p><p xmlns="http://www.w3.org/1999/xhtml">SOYOUNG PARK</p><p xmlns="http://www.w3.org/1999/xhtml">Soyoung Park brings more than two decades of experience in strategy and advisory within the bio-healthcare sector, including IQVIA, A.T. Kearney, and Oliver Wyman. She currently serves as Managing Director of Strategy Planning at GC Corporation. Her background strengthens Made Scientific&#39;s strategic planning capabilities and supports alignment with global partners, including long-term collaboration with GC Corporation.</p><p xmlns="http://www.w3.org/1999/xhtml">JIN PYUN</p><p xmlns="http://www.w3.org/1999/xhtml">Jin Pyun is CEO of GC Ventures and brings more than 25 years of experience across the global healthcare ecosystem, including biopharma, digital health, and healthcare delivery. He has held leadership roles at Pfizer, Nobilis Health ((formerly, NYSE:<a class="ticker" href="https://www.benzinga.com/quote/HLTH">HLTH</a>), WebMD, and HealthTap, driving commercialization and market development strategies across both B2C and B2B healthcare platforms.</p><p xmlns="http://www.w3.org/1999/xhtml">HARRY S. RATHORE, Ph.D.</p><p xmlns="http://www.w3.org/1999/xhtml">Harry S. Rathore brings over 40 years of leadership experience across the pharma life sciences and CDMO sector specializing in small molecules and biologics. He currently serves on several boards, including Gannet Biochem and Ascensus Specialties and is a Founder &amp; CEO of Symmetra Biosciences — an advisory practice dedicated to CDMO and PE clients. Previously, Harry has held chief executive roles at Borregaard Synthesis, Lonza India, Callery LLC, and Polyorganix, Inc.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About Made Scientific</b></p><p xmlns="http://www.w3.org/1999/xhtml">Made Scientific is a U.S.-based cell therapy contract development and manufacturing organization (CDMO) specializing in the development, manufacturing, and release of autologous and allogeneic cell therapy products for clinical and commercial supply. Headquartered in Princeton, New Jersey, Made Scientific combines the agility of a specialist CDMO with the deep technical expertise to deliver reliable and scalable solutions, supported by their long-term strategic backer, GC Corporation, a global leader in the pharmaceutical and biotechnology sectors. For more information, visit madescientific.com.</p><p xmlns="http://www.w3.org/1999/xhtml">Media Contact</p><p xmlns="http://www.w3.org/1999/xhtml">Lucy Taylor<br xmlns="http://www.w3.org/1999/xhtml"></br>Head of Marketing<br xmlns="http://www.w3.org/1999/xhtml"></br>Made Scientific, Inc.<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:media@madescientific.com" target="_blank" rel="nofollow">media@madescientific.com</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=NY48197&amp;sd=2026-04-30"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/made-scientific-strengthens-board-to-support-scale-up-and-commercial-readiness-in-cell-therapy-manufacturing-302759103.html" target="_blank">https://www.prnewswire.com/news-releases/made-scientific-strengthens-board-to-support-scale-up-and-commercial-readiness-in-cell-therapy-manufacturing-302759103.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Made Scientific, Inc.</p>

HLTH

Made Scientific Strengthens Board to Support Scale-Up and Commercial Readiness in Cell Therapy Manufacturing

Made Scientific bolsters Board to enhance cell therapy manufacturing growth

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>PRINCETON, N.J., April 30, 2026 /PRNewswire/ -- Made Scientific, a U.S.-based contract development and manufacturing organization (CDMO) specializing in cell therapies, today announced the continued build-out of its</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Made Scientific has strengthened its Board of Directors with new appointments to support its rapid growth in cell therapy manufacturing. This strategic governance aligns with their expansion of GMP manufacturing capacity, positioning the firm favorably to meet rising demand in the sector.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Made Scientific appointed Ted Dolan and Soyoung Park to its Board.</li><li>Board strengthens governance for upcoming growth phase in cell therapies.</li><li>Expansion of GMP manufacturing capacity in Princeton, NJ, to meet demand.</li><li>Partnership with GC Corporation ensures stability and sustained business investment.</li><li>Board members bring extensive experience in healthcare and CDMO sectors.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Made Scientific</strong>: Specializes in CDMO for cell therapies, growth signals positive.</li><li><strong>GC Corporation</strong>: Long-term investor providing stability and alignment in strategy.</li><li><strong>HLTH (HLTH)</strong>: Formerly Nobilis Health, may benefit from broader healthcare sector developments.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The category fits as a &#039;Corporate Development&#039; due to strategic Board appointments supporting growth initiatives. This is critical for investor monitoring as governance changes can impact operational strategies and performance forecasts significantly.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>New Board members bring significant experience, potentially improving operational efficiency.</li><li>Expansion of manufacturing capacity could lead to increased revenue for Made Scientific.</li><li>Strong partnership with GC Corporation may stabilize the business and drive growth.</li><li>Rising demand for cell therapies could benefit HLTH through acquired networks.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Made Scientific appointed Ted Dolan and Soyoung Park to its Board on April 30, 2026.</li><li>The company is expanding its GMP manufacturing capacity in Princeton, NJ.</li><li>GC Corporation is a long-term strategic shareholder backing Made Scientific.</li><li>The Board now includes members with experience in pharmaceutical manufacturing and strategic planning.</li><li>Made Scientific specializes in cell therapy development and manufacturing.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider a bullish position on HLTH as Made Scientific&#039;s growth may enhance investor sentiment.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">PRINCETON, N.J.</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">April 30, 2026</span> /PRNewswire/ -- Made Scientific, a U.S.-based contract development and manufacturing organization (CDMO) specializing in cell therapies, today announced the continued build-out of its Board of Directors, including the appointment of Ted Dolan and Soyoung Park. They join Jin Pyun, Harry S. Rathore, Ph.D., and Yonghoon Kim, alongside Chairman and CEO Syed T. Husain, as part of a deliberate effort to align the company&#39;s governance with its next phase of growth.</p>
    <div xmlns="http://www.w3.org/1999/xhtml" class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1">
                <p xmlns="http://www.w3.org/1999/xhtml">
                        <a xmlns="http://www.w3.org/1999/xhtml" href="https://mma.prnewswire.com/media/2642492/Made_Scientific_Logo.html" target="_blank" rel="nofollow">
                    <img xmlns="http://www.w3.org/1999/xhtml" src="https://mma.prnewswire.com/media/2642492/Made_Scientific_Logo.jpg" title="Made Scientific, Inc. (PRNewsfoto/Made Scientific, Inc)" alt="Made Scientific, Inc. (PRNewsfoto/Made Scientific, Inc)"></img>
                        </a>
                </p>
    </div>
<p xmlns="http://www.w3.org/1999/xhtml">Over the past year, Made Scientific has assembled a Board with deep experience spanning CDMO operations, global commercialization, the broader healthcare ecosystem, strategic planning, and financial stewardship. With these additions, the Board further strengthens its ability to support the company&#39;s transition toward late-phase and commercial cell therapy manufacturing.</p><p xmlns="http://www.w3.org/1999/xhtml">This evolution comes as Made Scientific expands its GMP manufacturing capacity at its Princeton, NJ campus to meet increasing demand from advanced therapy developers. As programs move closer to commercialization, the ability to scale operations, ensure operational discipline, and execute reliably becomes critical — areas where the Board brings direct, relevant experience.</p><p xmlns="http://www.w3.org/1999/xhtml">Made Scientific is supported by GC Corporation, a long-term strategic shareholder providing stability, global perspective, and sustained investment in the business. This partnership reflects a shared commitment to building deliberately — prioritizing scale and quality over short-term outcomes — and positions Made Scientific to advance cell therapy manufacturing with a long-term vision.</p><p xmlns="http://www.w3.org/1999/xhtml">&#34;As both Chairman and CEO, I&#39;ve been very intentional about how we&#39;ve built this Board over time,&#34; said Syed T. Husain. &#34;These are leaders who understand how to scale in complex environments and how therapies move through the broader healthcare ecosystem. With the addition of Ted and Soyoung, we are even better positioned to execute as we expand capacity, support increasingly complex and late-stage programs, and continue progressing toward becoming a leading cell therapy CDMO partner.&#34;</p><p xmlns="http://www.w3.org/1999/xhtml">Board of Directors</p><p xmlns="http://www.w3.org/1999/xhtml">SYED T. HUSAIN</p><p xmlns="http://www.w3.org/1999/xhtml">Syed T. Husain serves as Chairman and Chief Executive Officer of Made Scientific, bringing deep experience across the CDMO spectrum from development through commercialization of established and emerging therapeutic modalities, and leading the company&#39;s evolution toward late-phase and commercial cell therapy manufacturing. He previously served as Chief Commercial Officer at Resilience, where he drove commercial growth and established strategic partnerships. Earlier in his career, he held senior leadership roles at Emergent BioSolutions, Alcami Corporation, and Lonza.</p><p xmlns="http://www.w3.org/1999/xhtml">TED DOLAN</p><p xmlns="http://www.w3.org/1999/xhtml">Ted Dolan brings more than 40 years of CDMO and pharmaceutical manufacturing leadership across drug substance, drug product, and analytical services. He most recently served as COO of BioVectra and has held senior leadership roles at Alcami, Lonza, and Johnson Matthey. He adds deep operational expertise in scaling manufacturing organizations and driving execution across complex programs.</p><p xmlns="http://www.w3.org/1999/xhtml">YONGHOON KIM</p><p xmlns="http://www.w3.org/1999/xhtml">Yonghoon Kim brings extensive experience in global investment and financial management. He currently serves as CFO of MOHABI Investment USA, Inc., with prior experience at international investment and accounting firms including PwC Korea and NH Investment &amp; Securities (formerly Woori Investment &amp; Securities).</p><p xmlns="http://www.w3.org/1999/xhtml">SOYOUNG PARK</p><p xmlns="http://www.w3.org/1999/xhtml">Soyoung Park brings more than two decades of experience in strategy and advisory within the bio-healthcare sector, including IQVIA, A.T. Kearney, and Oliver Wyman. She currently serves as Managing Director of Strategy Planning at GC Corporation. Her background strengthens Made Scientific&#39;s strategic planning capabilities and supports alignment with global partners, including long-term collaboration with GC Corporation.</p><p xmlns="http://www.w3.org/1999/xhtml">JIN PYUN</p><p xmlns="http://www.w3.org/1999/xhtml">Jin Pyun is CEO of GC Ventures and brings more than 25 years of experience across the global healthcare ecosystem, including biopharma, digital health, and healthcare delivery. He has held leadership roles at Pfizer, Nobilis Health ((formerly, NYSE:<a class="ticker" href="https://www.benzinga.com/quote/HLTH">HLTH</a>), WebMD, and HealthTap, driving commercialization and market development strategies across both B2C and B2B healthcare platforms.</p><p xmlns="http://www.w3.org/1999/xhtml">HARRY S. RATHORE, Ph.D.</p><p xmlns="http://www.w3.org/1999/xhtml">Harry S. Rathore brings over 40 years of leadership experience across the pharma life sciences and CDMO sector specializing in small molecules and biologics. He currently serves on several boards, including Gannet Biochem and Ascensus Specialties and is a Founder &amp; CEO of Symmetra Biosciences — an advisory practice dedicated to CDMO and PE clients. Previously, Harry has held chief executive roles at Borregaard Synthesis, Lonza India, Callery LLC, and Polyorganix, Inc.</p><p xmlns="http://www.w3.org/1999/xhtml"><b xmlns="http://www.w3.org/1999/xhtml">About Made Scientific</b></p><p xmlns="http://www.w3.org/1999/xhtml">Made Scientific is a U.S.-based cell therapy contract development and manufacturing organization (CDMO) specializing in the development, manufacturing, and release of autologous and allogeneic cell therapy products for clinical and commercial supply. Headquartered in Princeton, New Jersey, Made Scientific combines the agility of a specialist CDMO with the deep technical expertise to deliver reliable and scalable solutions, supported by their long-term strategic backer, GC Corporation, a global leader in the pharmaceutical and biotechnology sectors. For more information, visit madescientific.com.</p><p xmlns="http://www.w3.org/1999/xhtml">Media Contact</p><p xmlns="http://www.w3.org/1999/xhtml">Lucy Taylor<br xmlns="http://www.w3.org/1999/xhtml"></br>Head of Marketing<br xmlns="http://www.w3.org/1999/xhtml"></br>Made Scientific, Inc.<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" href="mailto:media@madescientific.com" target="_blank" rel="nofollow">media@madescientific.com</a></p>



<p xmlns="http://www.w3.org/1999/xhtml" id="PURL"><img xmlns="http://www.w3.org/1999/xhtml" title="Cision" width="12" height="12" alt="Cision" src="https://edge.prnewswire.com/c/img/favicon.png?sn=NY48197&amp;sd=2026-04-30"></img> View original content to download multimedia:<a xmlns="http://www.w3.org/1999/xhtml" id="PRNURL" rel="nofollow" href="https://www.prnewswire.com/news-releases/made-scientific-strengthens-board-to-support-scale-up-and-commercial-readiness-in-cell-therapy-manufacturing-302759103.html" target="_blank">https://www.prnewswire.com/news-releases/made-scientific-strengthens-board-to-support-scale-up-and-commercial-readiness-in-cell-therapy-manufacturing-302759103.html</a></p><p xmlns="http://www.w3.org/1999/xhtml">SOURCE Made Scientific, Inc.</p>

Made Scientific has strengthened its Board of Directors with new appointments to support its rapid growth in cell therapy manufacturing. This strategic governance aligns with their expansion of GMP manufacturing capacity, positioning the firm favorably to meet rising demand in the sector.

Made Scientific Strengthens Board to Support Scale-Up and Commercial Readiness in Cell Therapy Manufacturing

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News